MLchartDataset catalogue

Taragarestrant

Term · Oncology and biomedicine · MLC-T-ONC-016983

An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, taragarestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.

Table 1. Record
IdentifierMLC-T-ONC-016983
FieldOncology and biomedicine
Synonymsselective estrogen receptor downregulator D-0502; SERD D-0502
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016983",
  "term": "Taragarestrant",
  "field": "Oncology and biomedicine",
  "definition": "An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, taragarestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.",
  "synonyms": [
    "selective estrogen receptor downregulator D-0502",
    "SERD D-0502"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/taragarestrant/"
}

Record 15,992 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.